Four Key Considerations to Help Prepare for the Next Public Health Threat

As a CDMO, Emergent has been working for more than two decades to develop, manufacture, and deliver protections against public health threats and deliver vaccines and therapeutic products for clients. In its work with biopharma and biotechnology businesses, as well as government and nongovernment organizations, Emergent provides the technology, expertise, and talent to help quickly and efficiently ramp up manufacturing and development for its clients' products.

During COVID-19, Emergent deployed new processes and technologies to manufacture novel coronavirus vaccines and therapeutic candidates for CDMO clients. That experience has doubled as a learning opportunity for the future. In this article, Emergent team members reflect on lessons learned through COVID-19 and share four considerations to help prepare for the next public health threat.

Read Article

 

EMERGENT IN THE NEWS: COVID-19 General Coverage

Read the latest news coverage of Emergent's insights and involvement in the fight against COVID-19. Last Updated: Thursday,...

READ MORE

EXECUTIVE INTERVIEW – Emergent CDMO: A Molecule-to-Market Partner for Complex Biologics

For nearly 25 years, Emergent has developed, manufactured, and delivered their own innovative vaccines and biotherapeutic...

READ MORE

All Hands on Deck for Fill/Finish of Vaccines and Therapeutics

“Emergent has a long, successful history of working with the US government to develop, manufacture, and deliver safe and...

READ MORE